Identification

Name
Ramosetron
Accession Number
DB09290
Type
Small Molecule
Groups
Approved, Investigational
Description

Ramosetron is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”. It is only licensed for use in Japan and selected Southeast Asian countries.

Structure
Thumb
Synonyms
Not Available
External IDs
YM 060
Product Ingredients
IngredientUNIICASInChI Key
Ramosetron hydrochloride9551LHD87E132907-72-3XIXYTCLDXQRHJO-RFVHGSKJSA-N
International/Other Brands
IBset / Iribo / Nasea / Nozia
Categories
UNII
7ZRO0SC54Y
CAS number
132036-88-5
Weight
Average: 279.343
Monoisotopic: 279.137162179
Chemical Formula
C17H17N3O
InChI Key
NTHPAPBPFQJABD-LLVKDONJSA-N
InChI
InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
IUPAC Name
(5R)-5-(1-methyl-1H-indole-3-carbonyl)-4,5,6,7-tetrahydro-1H-1,3-benzodiazole
SMILES
CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2

Pharmacology

Indication

For the treatment of nausea and vomiting and diarrhea-predominant irritable bowel syndrome in males.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 3A
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AclidiniumAclidinium may increase the constipating activities of Ramosetron.Approved
AlcuroniumAlcuronium may increase the constipating activities of Ramosetron.Experimental
AlfentanilAlfentanil may increase the constipating activities of Ramosetron.Approved, Illicit
AlphacetylmethadolAlphacetylmethadol may increase the constipating activities of Ramosetron.Experimental, Illicit
AlphaprodineAlphaprodine may increase the constipating activities of Ramosetron.Illicit
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Ramosetron.Approved, Investigational, Vet Approved
Anisotropine MethylbromideAnisotropine Methylbromide may increase the constipating activities of Ramosetron.Approved
AtracuriumAtracurium may increase the constipating activities of Ramosetron.Approved, Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the constipating activities of Ramosetron.Approved
AtropineThe risk or severity of constipation can be increased when Atropine is combined with Ramosetron.Approved, Vet Approved
BenactyzineBenactyzine may increase the constipating activities of Ramosetron.Withdrawn
BenzatropineThe risk or severity of constipation can be increased when Benzatropine is combined with Ramosetron.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Ramosetron.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ramosetron.Approved
BezitramideBezitramide may increase the constipating activities of Ramosetron.Experimental, Illicit, Withdrawn
BiperidenBiperiden may increase the constipating activities of Ramosetron.Approved, Investigational
BornaprineBornaprine may increase the constipating activities of Ramosetron.Experimental
BrompheniramineThe risk or severity of constipation can be increased when Brompheniramine is combined with Ramosetron.Approved
BuprenorphineBuprenorphine may increase the constipating activities of Ramosetron.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Ramosetron.Approved
ButorphanolButorphanol may increase the constipating activities of Ramosetron.Approved, Illicit, Vet Approved
ButylscopolamineButylscopolamine may increase the constipating activities of Ramosetron.Approved, Investigational, Vet Approved
CaffeineThe metabolism of Ramosetron can be decreased when combined with Caffeine.Approved
CarbamazepineThe metabolism of Ramosetron can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilCarfentanil may increase the constipating activities of Ramosetron.Illicit, Investigational, Vet Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ramosetron.Approved
ChlorphenoxamineChlorphenoxamine may increase the constipating activities of Ramosetron.Withdrawn
CiprofloxacinThe metabolism of Ramosetron can be decreased when combined with Ciprofloxacin.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ramosetron.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Ramosetron.Approved, Vet Approved
CodeineThe therapeutic efficacy of Ramosetron can be decreased when used in combination with Codeine.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramosetron.Approved
CyclopentolateCyclopentolate may increase the constipating activities of Ramosetron.Approved
DarifenacinDarifenacin may increase the constipating activities of Ramosetron.Approved, Investigational
DesloratadineDesloratadine may increase the constipating activities of Ramosetron.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramosetron.Approved
DexetimideDexetimide may increase the constipating activities of Ramosetron.Withdrawn
DextromoramideDextromoramide may increase the constipating activities of Ramosetron.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the constipating activities of Ramosetron.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the constipating activities of Ramosetron.Approved, Investigational
DicyclomineDicyclomine may increase the constipating activities of Ramosetron.Approved
DihydrocodeineDihydrocodeine may increase the constipating activities of Ramosetron.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the constipating activities of Ramosetron.Experimental, Illicit
DihydromorphineDihydromorphine may increase the constipating activities of Ramosetron.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ramosetron.Approved
DiphenhydramineThe risk or severity of constipation can be increased when Diphenhydramine is combined with Ramosetron.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the constipating activities of Ramosetron.Approved, Illicit
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Ramosetron.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramosetron.Approved, Vet Approved
DPDPEDPDPE may increase the constipating activities of Ramosetron.Experimental
EmeproniumEmepronium may increase the constipating activities of Ramosetron.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Ramosetron.Approved, Investigational
EtanautineEtanautine may increase the constipating activities of Ramosetron.Experimental
EthanolRamosetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthopropazineEthopropazine may increase the constipating activities of Ramosetron.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramosetron.Approved
EthylmorphineEthylmorphine may increase the constipating activities of Ramosetron.Approved, Illicit
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ramosetron.Approved
EtorphineEtorphine may increase the constipating activities of Ramosetron.Illicit, Vet Approved
EtybenzatropineEtybenzatropine may increase the constipating activities of Ramosetron.Experimental
FentanylThe therapeutic efficacy of Ramosetron can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineFesoterodine may increase the constipating activities of Ramosetron.Approved
FlavoxateFlavoxate may increase the constipating activities of Ramosetron.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ramosetron.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ramosetron.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ramosetron.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Ramosetron is combined with Fluvoxamine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ramosetron.Approved, Investigational
GallamineGallamine may increase the constipating activities of Ramosetron.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the constipating activities of Ramosetron.Approved
GlycopyrroniumGlycopyrronium may increase the constipating activities of Ramosetron.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ramosetron.Approved, Investigational
HeroinHeroin may increase the constipating activities of Ramosetron.Approved, Illicit, Investigational
HomatropineHomatropine may increase the constipating activities of Ramosetron.Approved
HydrocodoneRamosetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydromorphone may increase the constipating activities of Ramosetron.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramosetron.Approved
HyoscyamineThe risk or severity of constipation can be increased when Hyoscyamine is combined with Ramosetron.Approved
IpratropiumThe risk or severity of constipation can be increased when Ipratropium is combined with Ramosetron.Approved
KetobemidoneKetobemidone may increase the constipating activities of Ramosetron.Approved, Investigational
LamotrigineThe risk or severity of constipation can be increased when Lamotrigine is combined with Ramosetron.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ramosetron.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the constipating activities of Ramosetron.Approved, Investigational
LevorphanolLevorphanol may increase the constipating activities of Ramosetron.Approved
LidocaineThe metabolism of Ramosetron can be decreased when combined with Lidocaine.Approved, Vet Approved
LofentanilLofentanil may increase the constipating activities of Ramosetron.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ramosetron.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Ramosetron.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Ramosetron.Approved
Magnesium sulfateThe therapeutic efficacy of Ramosetron can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ramosetron.Approved
MazaticolMazaticol may increase the constipating activities of Ramosetron.Experimental
MecamylamineMecamylamine may increase the constipating activities of Ramosetron.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ramosetron.Approved
MeptazinolMeptazinol may increase the constipating activities of Ramosetron.Experimental
MethadoneMethadone may increase the constipating activities of Ramosetron.Approved
Methadyl AcetateMethadyl Acetate may increase the constipating activities of Ramosetron.Approved, Illicit
MethanthelineMethantheline may increase the constipating activities of Ramosetron.Approved, Investigational
MethscopolamineMethscopolamine may increase the constipating activities of Ramosetron.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ramosetron.Approved
Methylscopolamine bromideMethylscopolamine bromide may increase the constipating activities of Ramosetron.Approved
MetixeneMetixene may increase the constipating activities of Ramosetron.Approved
MorphineMorphine may increase the constipating activities of Ramosetron.Approved, Investigational
NalbuphineNalbuphine may increase the constipating activities of Ramosetron.Approved
NicardipineThe risk or severity of constipation can be increased when Nicardipine is combined with Ramosetron.Approved, Investigational
NicomorphineNicomorphine may increase the constipating activities of Ramosetron.Experimental
NormethadoneNormethadone may increase the constipating activities of Ramosetron.Approved, Illicit
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ramosetron.Approved
OpiumOpium may increase the constipating activities of Ramosetron.Approved, Illicit
OrphenadrineOrphenadrine may increase the constipating activities of Ramosetron.Approved
OtiloniumThe risk or severity of constipation can be increased when Otilonium is combined with Ramosetron.Experimental, Investigational
OxitropiumOxitropium may increase the constipating activities of Ramosetron.Investigational
OxybutyninOxybutynin may increase the constipating activities of Ramosetron.Approved, Investigational
OxycodoneThe therapeutic efficacy of Ramosetron can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Ramosetron can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumOxyphenonium may increase the constipating activities of Ramosetron.Approved
PancuroniumPancuronium may increase the constipating activities of Ramosetron.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ramosetron.Approved, Investigational
ParoxetineThe risk or severity of constipation can be increased when Paroxetine is combined with Ramosetron.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Ramosetron.Experimental
PentazocinePentazocine may increase the constipating activities of Ramosetron.Approved, Vet Approved
PentoliniumPentolinium may increase the constipating activities of Ramosetron.Approved
PethidinePethidine may increase the constipating activities of Ramosetron.Approved
PhenazocinePhenazocine may increase the constipating activities of Ramosetron.Experimental
PhenglutarimidePhenglutarimide may increase the constipating activities of Ramosetron.Experimental
PhenobarbitalThe metabolism of Ramosetron can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidinePhenoperidine may increase the constipating activities of Ramosetron.Experimental
PipecuroniumPipecuronium may increase the constipating activities of Ramosetron.Approved
PirenzepinePirenzepine may increase the constipating activities of Ramosetron.Approved
PiritramidePiritramide may increase the constipating activities of Ramosetron.Approved, Investigational
PramipexoleRamosetron may increase the sedative activities of Pramipexole.Approved, Investigational
PregabalinThe therapeutic efficacy of Ramosetron can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramosetron.Approved, Vet Approved
ProcyclidineProcyclidine may increase the constipating activities of Ramosetron.Approved
PromethazineThe risk or severity of constipation can be increased when Promethazine is combined with Ramosetron.Approved, Investigational
PropanthelinePropantheline may increase the constipating activities of Ramosetron.Approved
PropiverinePropiverine may increase the constipating activities of Ramosetron.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Ramosetron is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Ramosetron.Approved, Vet Approved
QuetiapineThe risk or severity of constipation can be increased when Quetiapine is combined with Ramosetron.Approved
QuinidineQuinidine may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilRemifentanil may increase the constipating activities of Ramosetron.Approved
RifampicinThe metabolism of Ramosetron can be increased when combined with Rifampicin.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ramosetron.Approved
RopiniroleThe metabolism of Ramosetron can be decreased when combined with Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of constipation can be increased when Scopolamine is combined with Ramosetron.Approved, Investigational
SolifenacinSolifenacin may increase the constipating activities of Ramosetron.Approved
SufentanilSufentanil may increase the constipating activities of Ramosetron.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ramosetron.Approved, Investigational
TapentadolTapentadol may increase the constipating activities of Ramosetron.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ramosetron.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ramosetron.Investigational
TilidineTilidine may increase the constipating activities of Ramosetron.Experimental
TiotropiumTiotropium may increase the constipating activities of Ramosetron.Approved
TolterodineTolterodine may increase the constipating activities of Ramosetron.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ramosetron.Approved
TramadolThe risk or severity of constipation can be increased when Tramadol is combined with Ramosetron.Approved, Investigational
TrihexyphenidylTrihexyphenidyl may increase the constipating activities of Ramosetron.Approved
TrimebutineThe risk or severity of constipation can be increased when Trimebutine is combined with Ramosetron.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Ramosetron.Approved
TrimethaphanTrimethaphan may increase the constipating activities of Ramosetron.Approved, Investigational
TropatepineTropatepine may increase the constipating activities of Ramosetron.Experimental
TropicamideTropicamide may increase the constipating activities of Ramosetron.Approved, Investigational
TrospiumThe risk or severity of constipation can be increased when Trospium is combined with Ramosetron.Approved
TubocurarineTubocurarine may increase the constipating activities of Ramosetron.Approved
UmeclidiniumUmeclidinium may increase the constipating activities of Ramosetron.Approved
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ramosetron.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ramosetron.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Ramosetron.Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ramosetron.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ramosetron.Approved, Investigational
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ramosetron.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Fujii Y, Saitoh Y, Tanaka H, Toyooka H: Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery. Anesth Analg. 2000 Feb;90(2):472-5. [PubMed:10648342]
  2. Lee SH, Cho SY, Yoo KY, Jeong S: Population pharmacokinetics of ramosetron. J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):73-83. doi: 10.1007/s10928-015-9455-8. Epub 2015 Nov 11. [PubMed:26558626]
External Links
KEGG Drug
D08466
PubChem Compound
108000
PubChem Substance
310265182
ChemSpider
97112
BindingDB
50334454
ChEBI
135156
ChEMBL
CHEMBL1643895
Wikipedia
Ramosetron

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentAnterior Resection Syndrome1
1CompletedNot AvailableHealthy Volunteers / Plasma Concentration of YM0602
2CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2CompletedTreatmentCancer of the Ovary / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2Unknown StatusPreventionProphylaxis against postoperative nausea and vomiting / Tumors, Solid1
2Unknown StatusSupportive CareMalignancies, Hematologic1
3CompletedPreventionRadiotherapy Induced Nausea and Vomiting1
3CompletedTreatmentDiarrhea-predominant Irritable Bowel Syndrome2
3CompletedTreatmentNausea / Vomiting1
3CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
3Unknown StatusSupportive CareCancers / Malignancies1
3Unknown StatusTreatmentUterine Myoma, Ovary Neoplasm, Adenomyosis1
4CompletedNot AvailableIrritable Bowel Syndrome (IBS)1
4CompletedPreventionKnee Osteoarthritis (Knee OA)1
4CompletedPreventionPonv / Prolonged QTc Interval1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedSupportive CareCancers / Tumors1
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
4RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
4TerminatedPreventionFacial Bones Fracture1
4Unknown StatusPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedNot AvailableDiarrhea-predominant Irritable Bowel Syndrome1
Not AvailableCompletedPreventionArterial Hypotension / Coronary Artery Bypass Graft Triple Vessel1
Not AvailableCompletedPreventionLaparoscopic Marsupialization of Renal Cyst1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting5
Not AvailableCompletedSupportive CareMalignant Neoplasm of Colon1
Not AvailableCompletedTreatmentAbdominal mass1
Not AvailableNot Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableNot Yet RecruitingTreatmentC.Delivery; Surgery (Previous), Gynecological1
Not AvailableNot Yet RecruitingTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
Not AvailableRecruitingPreventionHysteroscopy1
Not AvailableRecruitingPreventionProstate Cancer1
Not AvailableUnknown StatusPreventionArterial Hypotension / Nausea and Vomiting / Shivering / Vasopressor1
Not AvailableUnknown StatusPreventionLaparoscopic Cholecystectomy / Nausea / Vomiting1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0696 mg/mLALOGPS
logP2.22ALOGPS
logP2.24ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.68ChemAxon
pKa (Strongest Basic)6.36ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.68 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity82.14 m3·mol-1ChemAxon
Polarizability31.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
N-alkylindoles
Direct Parent
N-alkylindoles
Alternative Parents
Indoles / Aryl alkyl ketones / N-methylpyrroles / Benzenoids / Vinylogous amides / Imidazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 2 more
Substituents
N-alkylindole / Indole / Aryl ketone / Aryl alkyl ketone / N-methylpyrrole / Substituted pyrrole / Benzenoid / Vinylogous amide / Imidazole / Azole
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Suzuki T, Sugimoto M, Koyama H, Mashimo T, Uchida I: Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology. 2004 Sep;101(3):660-5. [PubMed:15329590]

Drug created on October 29, 2015 15:13 / Updated on August 02, 2018 07:51